University of Patras
Συσχέτιση γονιδιωματικών βιοδεικτών σε γονίδια της οικογένειας KLF με τα επίπεδα της εμβρυϊκής αιμοσφαιρίνης στον άνθρωπο: προεκτάσεις στην εξατομίκευση της θεραπείας με υδροξυουρία ασθενών με β- τύπου αιμοσφαιρινοπάθειες
Abstract
dc:descriptionHemoglobinopathies, including sickle-cell disease (SCD) and beta-thalassemia are among the most common monogenic disorders worldwide. They are mainly characterized by either defective or downrated to absent synthesis of one of the two polypeptide chains of hemoglobin. To date, the therapeutic options for treatment are limited. One of the most promising therapeutic approaches is the induction of γ globin genes, in order to increase the fetal hemoglobin levels and, as a result, to improve the patients`clinical picture. Thus, a large number of studies currently focus on transcription factors involved in the regulation of fetal hemoglobin.The only drug found to transiently reactivate the γ globin levels in patients suffering from SCD, and which is currently approved by the Food and Drug Administration (FDA) is hydroxyurea (HU). Several studies regarding HU administration in β-type hemoglobinopathies resulted in highly variable responses among patients to HU.Kruppel like factors (KLFs) constitute a family of transcription factors with a wide range of functions, including the regulation of the expression of globin genes during the different human developmental stages.At the current study, four tagSNPs (tagging single nucleotide polymorphisms), namely the rs2242189, rs2236599, rs11142398 and rs980112, located in four different Klf genes (Klf3, Klf4, Klf9 and Klf10 respectively) were studied, in order to examine (i) whether they were associated with increased HbF levels, thus affecting the β-thalassemia patients` condition, and (ii) their possible association with HU response in double heterozygous (SCD and beta-thalassaemia) patients. For this purpose, blood samples from (a) healthy non-thalassemic individuals; (b) transfusion-dependent beta-thalassemic patients; (c) non-transfusion-dependent beta thalassemic patients and (d) double heterozygous (SCD/b-thal) patients were analyzed by genotyping the abovementioned SNPs. The double heterozygous patients, to whom HU was administered, were divided into responders and non-responders to HU treatment, using two different criteria: (i) the increase of HbF levels above 20% and (ii) the three-fold increase of HbF levels.Target sequences were amplified by PCR and genotyped by either RFLP (restriction fragment length polymorphism) or Sanger chromosequencing; statistical analysis on the genotypes` and alleles` frequencies followed.The results of our study showed that under the >20% level increase criterion the rs2236599, located in Klf4, seems to be related (p=0,0396) with the response of double heterozygous patients to HU and that rs980112, located in Klf10, seems to be associated (p=0,0431) with the increased fetal hemoglobin levels on non-transfusion-dependent thalassemia patients.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Stratopoulos, Apostolos
- Στρατόπουλος, Απόστολος
Subjects
dc:subject × 8Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/45910